Participated · Seed · Oct 2025

Cylerity applies artificial intelligence and machine-learning models to analyze healthcare insurance claims, predict reimbursement amounts, and instantly advance capital to providers. By shortening the months-long payment cycle to less than a day, the platform eases providers’ cash-flow constraints and lets them focus on patient care rather than collections. Its technology incorporates real-time receivables valuation and anomaly detection to price risk and identify underpayments. The company monetizes by charging a fee on the funds it advances, positioning itself as a financial intermediary rather than a traditional lender. Customer testimonials highlight its role in stabilizing payroll and supply costs during the pandemic. With fresh funding, Cylerity intends to grow its engineering and data-science teams and broaden partnerships with provider networks nationwide. The business is currently backed by several healthcare-focused and regional venture firms and has secured a dedicated debt facility to scale transaction volumes.

Participated · Seed · Aug 2023

Pelvital USA, Inc. is a women’s health medical device company based in Eagan, Minnesota, led by President and CEO Lydia Zeller. Its first product, Flyte, is an FDA-cleared, novel in-home treatment for stress urinary incontinence (SUI) and weakened pelvic floor muscles that delivers mechanotherapy to the pelvic floor. Flyte is reported effective for mild, moderate, and severe SUI, with a typical treatment regimen of five minutes per day for six weeks. The company positions Flyte as a convenient, clinician-backed pelvic floor therapy that can be used outside clinical settings. Pelvital recently closed an additional $2.32M in a seed-plus financing to accelerate commercialization of Flyte. Pelvital, based in Eagan, MN, develops Flyte, an FDA-cleared at-home intravaginal device that delivers mechanotherapy to treat stress urinary incontinence (SUI) and strengthen pelvic floor muscles. Flyte’s mechanism pairs mechanotherapy with an active pelvic floor contraction to stimulate tissue repair and create neuromuscular memory. The device was originally developed by physicians from the Arctic University of Norway with collaborators in gynecology, muscle rehabilitation, and urinary incontinence treatment. Pelvital is led by President and CEO Lydia Zeller. The company recently closed a $2.68M seed funding round, providing capital to complete development of its next-generation product. Management plans to use the proceeds to accelerate commercialization and expand reach to clinicians and women seeking conservative, in‑home SUI treatment.

Participated · Seed · Sep 2021

Agricycle Global partners with rural farmers in East Africa to upcycle excess food into ethically made ingredients sold to consumer packaged goods manufacturers in North America and Europe. The company produces 159 different ingredients, from cassava flour to gooseberries, and is supplying pilot medium and large CPG customers making cookies, crackers and premium dog food. Founded in 2015 as a school project by CEO Josh Shefner, Agricycle previously operated consumer brands Jali Fruit Co. and Tropicoal Ignition but is shifting focus to its ingredient supply brand, Field Better Ingredients. The company employs four full-time and four part-time staff at its Milwaukee headquarters and 55 full-time employees in East Africa. With the recent seed funding, Agricycle plans to acquire a fleet of trucks and a milling facility in Africa to more fully control and consolidate its supply chain, which it says helps it beat commodity prices. The funding is intended to scale ingredient supply into more products and onto more retail shelves.

Participated · Series A · Apr 2021

OnLume Surgical develops novel fluorescence-guided surgery (FGS) imaging systems for use during a range of surgical procedures. Its core product is an FDA-cleared FGS imaging system for fluorescence imaging of blood flow and tissue perfusion before, during and after vascular, gastrointestinal, organ transplant, plastic, reconstructive and microsurgeries. The system is designed to illuminate critical anatomy in real time to optimize precision, improve patient outcomes, reduce morbidity and lower costs. OnLume is also developing additional applications of its imaging platform, including tumor-specific fluorescent agents to help surgeons identify residual cancer tissue. Financially, the company completed a Series A financing raising over $7 million and previously received a $2 million Phase II SBIR grant from the National Cancer Institute. Proceeds are intended to support a commercial launch into its first market vertical and to advance other market opportunities over the next 24 months.

Participated · Seed · Feb 2021

C. Light develops neurotech and AI that uses retinal eye-tracking to map neurodegeneration and assess therapeutic efficacy. Its non-invasive technology measures fixational eye motion at the cellular scale (as small as 1/100th the size of a human hair). The company plans to study retinal eye motion biomarkers to flag diagnosis, prognosis and monitoring of Alzheimer’s disease in tandem with new drug therapies. A new investment will fund a pilot study with the UCSF Memory and Aging Center to examine changes in fixational eye motion during mild cognitive impairment. C. Light is led by co-founder Dr. Christy K. Sheehy and is based in Boston, MA. Financially, the company completed a second and final seed round of $500k (which included ADDF) and reports total seed funding of more than $3m; the most recent funding amount was undisclosed. C. Light Technologies develops a retinal eye-tracking device that assesses neurological health using a 10-second scan. Its device can image the retina down to the cellular level and track eye movements as small as one micron, measuring microsaccades that may predict neurodegenerative disease progression. The company intends to use the recent funding to hire a design and manufacturing firm to convert a working prototype into a finalized commercial product and to pursue 510(k) FDA clearance. It plans to fundamentally reshape monitoring and treatment options for Alzheimer’s, Parkinson’s, ALS and concussion recovery. C. Light closed a $2.5M seed round led by Creative Ventures, bringing total funding to more than $3.25M. Led by Co‑Founder and CEO Dr. Christy K. Sheehy, the company will relocate its corporate offices to Boston in February.